May 29, 2026 | Read online

First Look: (NASDAQ: GTBP) Just Landed On Our Early Morning Radar

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

GT Biopharma Advances Third TriKE® Into the Clinic — Why (NASDAQ: GTBP) Just Landed on Our Radar and Will be Topping Today’s Watchlist —Friday, May 29th, 2026

May 29, 2026

Dear Reader,

GT Biopharma, Inc. (NASDAQ: GTBP) is emerging as one of the more compelling setups in small-cap biopharma right now, and a recent clinical development adds fuel to the thesis.

The company recently announced that it dosed the first patient in a Phase 1 dose escalation basket trial of GTB-5550, its B7-H3-targeted natural killer (NK) cell engager designed to go after solid tumors.

This is now the third TriKE® candidate to enter the clinic — and the first to use a dual nanobody design with subcutaneous dosing, which could make it far more patient-friendly than IV-based immuno-oncology approaches.

That's a meaningful expansion beyond blood cancers and into solid tumor territory — an approach that could potentially open the door to seven different tumor types, including prostate, ovarian, breast, and pancreatic cancers.

Here's what makes this especially noteworthy: B7-H3, the target of GTB-5550, is expressed in over 90% of metastatic castration-resistant prostate cancer tumors — suggesting the company may have selected one of the most promising entry points in solid tumor immuno-oncology.

With clinical momentum building and a market tailwind at its back, this one deserves a closer look.

Keep reading to quickly get up to speed on why we're highlighting (GTBP) right now.

The bigger picture here is just as compelling.

According to Business Research Insights, the global NK cell therapy market is projected to reach $2.8B by 2035 — a 16.2% CAGR — with over 120 active clinical programs globally.

GT Biopharma is positioning itself at the center of that wave.

GT Biopharma, Inc. (NASDAQ: GTBP) is topping our watchlist this morning — Friday, May 29, 2026.

According to Yahoo Finance, (GTBP) has approximately 33.53M shares in its public float — with a float that tight, even a small shift in demand could spark outsized moves.

Here's what the company actually does — and why their science matters.

GT Biopharma is a clinical-stage biopharmaceutical company headquartered in San Francisco, focused on developing and commercializing immuno-oncology therapies built on its proprietary TriKE® NK cell engager platform.

The TriKE® platform is designed to harness and supercharge a patient's own natural killer cells to seek out and destroy cancer.

The company holds an exclusive worldwide license with the University of Minnesota to further develop and commercialize all TriKE® therapies.

What really stands out is the next-generation tech. GT Biopharma's second-generation platform — the Camelid Nanobody TriKE® — has shown 10–40x greater potency than the original TriKE® design in preclinical studies, with a smaller molecular footprint that may offer superior biodistribution in solid tumors.

That's the kind of leap that separates a one-trick pipeline from a true platform story.

Clinical Momentum Building on Multiple Fronts

GTB-5550 Phase 1 launched: The company recently announced it dosed the first patient in the Phase 1 dose escalation basket trial of GTB-5550 for B7-H3-positive solid tumors. Updates are expected in the second half of 2026 as enrollment progresses through dose escalation cohorts.
GTB-3650 advancing through cohorts: According to the May 15 press release, eight patients have now been treated across four cohorts in the GTB-3650 Phase 1 study for AML/MDS, with Cohort 5 expected to begin dosing in Q2 2026. Longer-term follow-up data from earlier cohorts is anticipated in Q3 2026.
Three TriKE® candidates now in clinic or pipeline: GTB-3650 (CD33, AML/MDS), GTB-5550 (B7-H3, solid tumors), and GTB-7550 (CD19, lymphoid malignancies and autoimmune disease) — giving GT Biopharma a diversified clinical portfolio across both oncology and autoimmune indications.
Cash runway through Q4 2026: The company reported approximately $9M in cash and equivalents as of March 31, 2026, sufficient to fund operations through the end of the year.
Leadership confidence: CEO Michael Breen stated that advancing three TriKE® candidates into the clinic represents a significant milestone — and confirmed the company looks forward to providing updates on both active programs in the second half of 2026.

The clinical pipeline is moving — but the market tailwind behind it tells an equally compelling story.

NK Cell Therapy: A Market Set to Explode

According to Business Research Insights, the NK cell therapy space is one of the fastest-growing segments in immuno-oncology. Here's what the growth trajectory looks like:

NK Cell Therapy Market: $0.86B (2026) → $2.8B (2035) at a 16.2% CAGR
Broader Cell Therapy Market: $5.58B (2025) → $14.56B (2031) at a 17.05% CAGR, with NK cell programs expanding at a 12.78% CAGR within that segment
Off-the-Shelf Allogeneic Platforms: The fastest-growing subsegment at 12.56% CAGR through 2030 — and GT Biopharma's TriKE® platform fits squarely in this lane

More than 120 active clinical programs globally are now focused on NK cell-based approaches, with oncology applications dominating adoption. GT Biopharma isn't just participating in this space — it's pioneering a differentiated engagement platform that could stand apart from the pack.

With all of that laid out, here's the condensed case for why this name deserves attention right now.

6 Reasons (GTBP) Is on Our Radar

First-of-its-kind subcutaneous dosing: Per the FDA IND clearance announcement, GTB-5550 is the first dual nanobody TriKE® to use subcutaneous delivery instead of IV, making it more patient-friendly and potentially reducing administration costs versus competing immuno-oncology approaches.
Built-in biomarker advantage: According to the FDA clearance press release, B7-H3 is expressed in over 90% of metastatic castration-resistant prostate cancer tumors, and PSA can serve as an early readout of therapeutic activity — giving this trial a built-in signal detection edge that many Phase 1 oncology programs lack.
Massive addressable patient population: According to the IND submission announcement, the GTB-5550 Phase 1b expansion could enroll across seven different solid tumor types — prostate, ovarian, breast, head & neck, NSCLC, pancreatic, and bladder — representing enormous unmet need across multiple indications.
Next-gen science with a 10–40x potency edge: Based on GT Biopharma's pipeline overview, the Camelid Nanobody TriKE® architecture has outperformed the first-generation design by 10–40x in preclinical anti-tumor models. A more compact molecular structure could also mean better tissue penetration — a critical advantage when going after hard-to-reach solid tumors.
Clean safety profile building clinical confidence: According to the May 15 press release, GTB-3650 has demonstrated an excellent safety and tolerability profile across the first four dosing cohorts, with eight patients treated and no dose-limiting toxicities reported — a track record that strengthens the foundation as additional TriKE® candidates enter the clinic.
Autoimmune expansion could reshape the story: According to GT Biopharma's pipeline overview, GTB-7550 isn't confined to cancer — the CD19-targeted TriKE® is also being explored for autoimmune conditions like lupus, backed by early preclinical B-cell depletion data. If that direction gains traction, it could open the door to a multi-billion-dollar therapeutic market that most names at this valuation don't have a shot at.

Pull up (GTBP) Today…

Worth noting: with a micro-cap valuation of just ~$15.92M and a float of roughly 33.53M shares, (GTBP) appears to be trending under-the-radar.

The company now has three TriKE® candidates advancing — two in active Phase 1 trials and one in preclinical development — yet the current valuation barely reflects a single program, let alone a full platform.

It wouldn't take much renewed attention for this name to start getting reevaluated.

Here's the bottom line: a next-generation NK cell engager platform with three clinical-stage candidates, subcutaneous dosing innovation, a massive addressable market projected to reach $2.8B by 2035, an exclusive worldwide license on the entire TriKE® technology, and a micro-cap valuation that doesn't yet reflect any of it.

We have all eyes on (GTBP) this morning—Friday, May 29, 2026.

Sincerely,

Ryan Stryker
Senior Editor
Alpha Wire Daily

^{AlphaWireDaily.com}^{(“AlphaWireDaily” or “AWD” ) is owned by GG Media Holdings LLC, a multi member limited liability company. Data is provided from third-party sources and AWD is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile AWD brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.}

^{Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 05/29/2026 and ending on 05/29/2026 to publicly disseminate information about (GTBP:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, GG Media Holdings LLC has been paid thirty seven thousand five hundred USD (“Funds”). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from GT Biopharma Inc., the issuer of (GTBP:US).}

^{Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (GTBP:US).}

^{Please see important disclosure information here:}^{https://alphawiredaily.com/disclosure/gtbp-2B4ek/#details}